Paper20122366
A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
McElroy SL and 10 others. J Clin Psychiatry, 2010. Cited by 233 papers, by iCite.
Cite this record
ConductScience Library. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Papers, record 20122366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20122366
- Disease
- bipolar disorder173 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antidepressive Agents | Major topic |
| Antidepressive Agents, Second-Generation | Major topic |
| Antimanic Agents | Major topic |
| Bipolar Disorder | Major topic |
| Dibenzothiazepines | Major topic |
| Paroxetine | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Placebos | |
| Psychiatric Status Rating Scales | |
| Quetiapine Fumarate | |
| Severity of Illness Index | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00119652 | Seroquel in Bipolar Depression Versus SSRI | Derived from the trial | Yes |
Source ClinicalTrials.gov
Cited by94
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 233 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42968118 | INTENSIFY-a randomized, controlled trial to investigate the effect of an early intensified pharmacological treatment for major psychiatric disorders after treatment failure in the current episode: a study protocol. | Trials | 2026 | https://conductscience.org/library/papers/42968118 | PubMed |
| 42278457 | The Role of the Ketogenic Diet in Modulating Biochemical Pathophysiology in Psychiatric and Neurodegenerative Disorders. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278457 | PubMed |
| 42204011 | Efficacy and safety of pharmacological and non-invasive brain stimulation for adolescent bipolar depression: a systematic review and network meta-analysis. | Int J Bipolar Disord | 2026 | https://conductscience.org/library/papers/42204011 | PubMed |
| 41856598 | Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol. | BMJ Open | 2026 | https://conductscience.org/library/papers/41856598 | PubMed |
| 40864439 | Antipsychotic Drugs and Dysregulated Glucose Homeostasis: A Systematic Review and Meta-Analysis. | JAMA Psychiatry | 2025 | https://conductscience.org/library/papers/40864439 | PubMed |
| 40823496 | Switch to mania after acute antidepressant treatment for bipolar depression: a systematic review and network meta-analysis of randomised controlled trials. | EClinicalMedicine | 2025 | https://conductscience.org/library/papers/40823496 | PubMed |
| 40694062 | Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial. | Int Clin Psychopharmacol | 2026 | https://conductscience.org/library/papers/40694062 | PubMed |
| 40630973 | Systematic Review of Second-Generation Antidepressant Monotherapy for Acute Bipolar-II Depression. | Psychopharmacol Bull | 2025 | https://conductscience.org/library/papers/40630973 | PubMed |
| 40355996 | Antidepressants in Bipolar Depression: From Neurotransmitter Mechanisms to Clinical Challenges. | Actas Esp Psiquiatr | 2025 | https://conductscience.org/library/papers/40355996 | PubMed |
| 39755917 | Untangling the complex relationship between bipolar disorder and anxiety: a comprehensive review of prevalence, prognosis, and therapy. | J Neural Transm (Vienna) | 2025 | https://conductscience.org/library/papers/39755917 | PubMed |
| 39754520 | Therapeutic Potential of Saffron Extract in Mild Depression: A Study of Its Role on Anhedonia in Rats and Humans. | Phytother Res | 2025 | https://conductscience.org/library/papers/39754520 | PubMed |
| 39170573 | Progress and trends of research on mineral elements for depression. | Heliyon | 2024 | https://conductscience.org/library/papers/39170573 | PubMed |
| 38487836 | Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis. | Eur Psychiatry | 2024 | https://conductscience.org/library/papers/38487836 | PubMed |
| 37683232 | Antidepressant-Associated Treatment Emergent Mania: A Meta-Analysis to Guide Risk Modeling Pharmacogenomic Targets of Potential Clinical Value. | J Clin Psychopharmacol | 2023 | https://conductscience.org/library/papers/37683232 | PubMed |
| 36513812 | Antidepressants that increase mitochondrial energetics may elevate risk of treatment-emergent mania. | Mol Psychiatry | 2023 | https://conductscience.org/library/papers/36513812 | PubMed |
| 35778967 | A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder. | Acta Psychiatr Scand | 2022 | https://conductscience.org/library/papers/35778967 | PubMed |
| 34658633 | Acute and Maintenance Treatment of Bipolar Depression. | Noro Psikiyatr Ars | 2021 | https://conductscience.org/library/papers/34658633 | PubMed |
| 33975574 | Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. | BMC Psychiatry | 2021 | https://conductscience.org/library/papers/33975574 | PubMed |
| 32047367 | Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better. | Focus (Am Psychiatr Publ) | 2019 | https://conductscience.org/library/papers/32047367 | PubMed |
| 31932883 | [German S3 guidelines on bipolar disorders-first update 2019 : What is new in pharmacotherapy?] | Nervenarzt | 2020 | https://conductscience.org/library/papers/31932883 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| QUETIAPINE FUMARATE | CHEMBL3188993 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3188993 | ChEMBL |
| PAROXETINE | CHEMBL490 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL490 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20122366
GET https://conductscience.org/api/papers/v1/20122366/cited_by?page=2